Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minor Jimenez GuevarafiledCriticalMinor Jimenez Guevara
Priority to CR9823ApriorityCriticalpatent/CR9823A/en
Publication of CR9823ApublicationCriticalpatent/CR9823A/en
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Peptides Or Proteins
(AREA)
Abstract
Se describen conjugados citotoxicos que comprenden un agente de enlace celular y un agente citotoxico, composiciones terapeuticas que comprenden el conjugado, metodos para usar los conjugados en la inhibicion del crecimiento celular y el tratamiento de la enfermedad, y un equipo que comprende el conjugado citotoxico en todas las modalidades de la invencion. En particular, el agente de enlace celular es un anticuerpo monoclonal, y fragmentos de enlace de epitope del mismo, que reconoce y enlaza el glicotopo CA6. La presente invencion tambien esta dirigida a versiones humanizadas o recubiertas de DS6, un anticuerpo monoclonal anti-CA6 murino, y fragmentos de enlace de epitope del mismo.Cytotoxic conjugates comprising a cell binding agent and a cytotoxic agent, therapeutic compositions comprising the conjugate, methods for using the conjugates in the inhibition of cell growth and the treatment of the disease, and a kit comprising the cytotoxic conjugate are described in all modalities of the invention. In particular, the cell binding agent is a monoclonal antibody, and epitope binding fragments thereof, which recognizes and binds the CA6 glyotope. The present invention is also directed to humanized or coated versions of DS6, a murine anti-CA6 monoclonal antibody, and epitope binding fragments thereof.
CR9823A2008-03-242008-03-24
AN ANTIGEN-SPECIFIC CA6 CYTOTOXIC CONJUGATE AND METHODS TO USE THE SAME
CR9823A
(en)
Human monoclonal antibody isolated because it binds to human mesothelin; composition comprising said antibody; conjugate between antibody and therapeutic agent; nucleic acid molecule that encodes the antibody; use to prepare a drug to treat cancer.
Monoclonal antibody that recognizes conformational epitope and binds to polymeric soluble amyloid peptides and oligomeric amyloid peptides, particularly to polymeric soluble amyloid abeta peptides and oligomeric amyloid abeta peptides; polynucleotides encoding said antibody; therapeutic composition comprising the antibody; use of the antibody to treat diseases and disorders caused or associated with amyloid proteins (div. sol. 1742-2008).
Human anti-rg1 monoclonal antibody conjugate or an antigen-binding portion thereof with associated molecules, which composition comprises; in vitro method for inhibiting the growth of a tumor cell expressing rg-1; use of this conjugate to treat cancer